ID

34394

Description

A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms; ODM derived from: https://clinicaltrials.gov/show/NCT01309789

Link

https://clinicaltrials.gov/show/NCT01309789

Keywords

  1. 1/17/19 1/17/19 -
Copyright Holder

see on clinicaltrials.gov

Uploaded on

January 17, 2019

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Lymphoma, Large-Cell, Anaplastic NCT01309789

Eligibility Lymphoma, Large-Cell, Anaplastic NCT01309789

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
treatment-naive cd30-positive mature t-cell and nk-cell neoplasms, including systemic anaplastic large cell lymphoma
Description

ID.1

Data type

boolean

measurable disease of at least 1.5 cm
Description

ID.2

Data type

boolean

ecog performance status less than or equal to 2
Description

ID.3

Data type

boolean

Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
known cerebral/meningeal disease, including history of progressive multifocal leukoencephalopathy
Description

ID.4

Data type

boolean

current diagnosis of primary cutaneous anaplastic large cell lymphoma, mycosis fungoides, sezary syndrome or other primary cutaneous lymphomas; extranodal nk/t-cell lymphoma, nasal type
Description

ID.5

Data type

boolean

history of another primary malignancy that has not been in remission for at least 3 years
Description

ID.6

Data type

boolean

left ventricular ejection fraction <45% or symptomatic cardiac disease, or myocardial infarction within the past 12 months
Description

ID.7

Data type

boolean

viral, bacterial, or fungal infection within two weeks prior to the first dose of brentuximab vedotin
Description

ID.8

Data type

boolean

known human immunodeficiency virus (hiv), hepatitis b virus, or hepatitis c virus positive status
Description

ID.9

Data type

boolean

Similar models

Eligibility Lymphoma, Large-Cell, Anaplastic NCT01309789

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
treatment-naive cd30-positive mature t-cell and nk-cell neoplasms, including systemic anaplastic large cell lymphoma
boolean
ID.2
Item
measurable disease of at least 1.5 cm
boolean
ID.3
Item
ecog performance status less than or equal to 2
boolean
Item Group
C0680251 (UMLS CUI)
ID.4
Item
known cerebral/meningeal disease, including history of progressive multifocal leukoencephalopathy
boolean
ID.5
Item
current diagnosis of primary cutaneous anaplastic large cell lymphoma, mycosis fungoides, sezary syndrome or other primary cutaneous lymphomas; extranodal nk/t-cell lymphoma, nasal type
boolean
ID.6
Item
history of another primary malignancy that has not been in remission for at least 3 years
boolean
ID.7
Item
left ventricular ejection fraction <45% or symptomatic cardiac disease, or myocardial infarction within the past 12 months
boolean
ID.8
Item
viral, bacterial, or fungal infection within two weeks prior to the first dose of brentuximab vedotin
boolean
ID.9
Item
known human immunodeficiency virus (hiv), hepatitis b virus, or hepatitis c virus positive status
boolean

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial